Cutting-edge bioengineering-as-a-service company Ginkgo Bioworks (NYSE: DNA) gave investors an update on its third-quarter earnings on Nov. 8. When it did, management provided hard data as well as a handful of clues about the company's near-term future.

Here are three of the most important things to keep an eye on. All three are especially important considerations if you're thinking about starting a position in the stock.

Ginkgo has two core goals right now: growth and profitability. Management thinks that due to economies of scale in bioengineering and biomanufacturing, the business should be able to pursue both of those goals at once. The idea is that by getting more projects running on its platform comprised of industrial-scale laboratory automation, robotics, and artificial intelligence (AI), the cost of serving each project will drop.

Continue reading

Source Fool.com